Alvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics Platform

Alvogen Completes Comprehensive Refinancing

Alvogen Issues Voluntary Nationwide Recall for One Lot of Fentanyl Transdermal System 25 mcg/h Due to a Defective Delivery System

A powerful investment alliance of Aztiq and Innobic acquires Alvogen’s shares in Lotus and Adalvo in a US$475m deal

Newly issued share equity in Alvogen US acquired by Aztiq Pharma Partners

Alvogen and sister company Alvotech donate 100 thousand US dollars to UNICEF in combat against COVID-19

One of the guiding principles at Alvogen has always been to give back to the communities in which we serve, but Dr. Chandrashekhar Nimkar has clearly taken this to a whole new level, as a philanthropist with both a global and local reach.

Frontline warrior against COVID-19

Alvogen and Alvotech launch new B2B business brand

Alvogen’s subsidiary in Asia, Lotus Pharmaceuticals announces new global partnerships to drive growth

Alvogen completes sale of its Central and Eastern European business to Zentiva Group

Alvogen submits European application for generic Pazopanib

Delivering on our promise during the Coronavirus Pandemic

Kick-Off Meeting in Mexico

Alvotech and JAMP Pharma enter into an exclusive partnership for the commercialization of key biosimilars in Canada

Alvogen and Yas Holding announce license and distribution agreement to commercialize generics portfolio in MENA Region

Alvogen at CPhI 2019

Alvogen announces divestment of its Central and Eastern European Business to Zentiva Group

Alvogen announces exclusive commercialization agreements in South Korea, Israel and Canada for Teriparatide (PF708)

Latest News